Incannex Healthcare

Contributing Author

Recent Articles by Incannex Healthcare

Aug-22	Incannex Healthcare Authorizes $20 Million Share Repurchase Program IXHL +28.52% GlobeNewswire
Aug-08	Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea IXHL GlobeNewswire
Jul-31	Incannex Confirms Strong Cash Position; No Plans or Requirement to Fully Utilise ATM in Near Term IXHL GlobeNewswire
Jul-30	Incannex Reports Positive Topline Results from RePOSA Phase 2 Trial of IHL-42X IXHL GlobeNewswire
Jul-25	Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Charlene E. Gamaldo IXHL GlobeNewswire
Jun-24	Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Douglas B. Kirsch IXHL GlobeNewswire
Jun-18	Incannex achieves key milestone with database lock for RePOSA Phase 2 trial of IHL-42X IXHL GlobeNewswire
Jun-17	Incannex Healthcare Forms Joint Venture with Mind Medicine Australia to Expand Access to Psychedelic-Assisted Therapy IXHL GlobeNewswire
Jun-12	Incannex Healthcare Cancels All Outstanding Series A Warrants Following Strategic ATM Execution IXHL GlobeNewswire
Jun-03	Incannex Healthcare Inc. Expands IHL-42X Clinical Advisory Board with Appointments of Four Industry and Academic Leaders to Advance Obstructive Sleep Apnea (OSA) Program IXHL GlobeNewswire
May-29	Incannex Healthcare Inc. Advances IHL-42X RePOSA Trial to Phase 3 Following FDA Protocol Clearance IXHL GlobeNewswire
May-28	Incannex Healthcare Inc. Enters Agreement to Cancel Remaining Series A Warrants, Eliminating Up to 347.2 Million Shares from Potential Dilution Ahead of IHL-42X Phase 2 Topline Results IXHL GlobeNewswire
May-20	Incannex Healthcare Inc. Executes Strategic Cancellation of 50.4% of Series A Warrants, Significantly Reducing Potential Dilution IXHL GlobeNewswire
May-16	Incannex Announces Potential Reduction of Up to 50.4% of its Series A Warrants IXHL GlobeNewswire
May-15	Incannex Healthcare Inc. Reports Fiscal Third Quarter 2025 Financial Results and Business Updates IXHL GlobeNewswire
May-14	Incannex Healthcare Inc. Provides Clinical Program Update on IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA) IXHL GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.